$185.39
0.09% yesterday
NYSE, Jun 25, 10:10 pm CET
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

AbbVie Stock price

$185.39
+2.13 1.16% 1M
+5.39 2.99% 6M
+7.69 4.33% YTD
+14.64 8.57% 1Y
+32.25 21.06% 3Y
+88.40 91.14% 5Y
+115.57 165.53% 10Y
+150.39 429.69% 20Y
NYSE, Closing price Wed, Jun 25 2025
-0.16 0.09%
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

Key metrics

Basic
Market capitalization
$327.5b
Enterprise Value
$392.2b
Net debt
$64.7b
Cash
$5.2b
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
78.89 | 27.86
P/S
5.71 | 5.48
EV/Sales
6.84 | 6.56
EV/FCF
25.49
P/B
230.61
Dividends
DPS
$6.29
Yield 1Y | 5Y
3.39% | 4.15%
Growth 1Y | 5Y
5.01% | 7.46%
Payout 1Y | 3Y
263.18% | 153.24%
Increased
13 Years
Financials (TTM | estimate)
Revenue
$57.4b | $59.9b
EBITDA
$25.8b | $28.3b
EBIT
$17.5b
Net Income
$4.2b | $11.8b
Free Cash Flow
$15.4b
Growth (TTM | estimate)
Revenue
5.45% | 6.24%
EBITDA
4.86% | 13.85%
EBIT
9.32%
Net Income
-30.17% | 177.58%
Free Cash Flow
-29.72%
Margin (TTM | estimate)
Gross
70.69%
EBITDA
44.99% | 47.33%
EBIT
30.43%
Net
7.24% | 19.66%
Free Cash Flow
26.82%
Financial Health
Equity Ratio
2.46%
Return on Equity
127.46%
ROCE
17.50%
ROIC
-
Debt/Equity
49.22
More
EPS
$2.35
FCF per Share
$8.71
Short interest
0.90%
Employees
55.00k
Rev per Employee
$1.02m
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a AbbVie forecast:

18x Buy
60%
12x Hold
40%

Analyst Opinions

30 Analysts have issued a AbbVie forecast:

Buy
60%
Hold
40%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
57,367 57,367
5% 5%
100%
- Direct Costs 16,812 16,812
8% 8%
29%
40,555 40,555
12% 12%
71%
- Selling and Administrative Expenses 14,686 14,686
13% 13%
26%
- Research and Development Expense 8,419 8,419
15% 15%
15%
25,808 25,808
5% 5%
45%
- Depreciation and Amortization 8,351 8,351
3% 3%
15%
EBIT (Operating Income) EBIT 17,457 17,457
9% 9%
30%
Net Profit 4,155 4,155
30% 30%
7%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Neutral
GlobeNewsWire
about 15 hours ago
The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key growth drivers include rising ovarian cancer prevalence, healthcare access in emerging markets, and increased demand for personalized medicine. Despite challenges like high costs and competition, the market, led by AbbVie Inc. (ImmunoGen), presents vast opportunities, particul...
Neutral
Seeking Alpha
about 16 hours ago
Markets remained volatile in May 2025 amid ongoing trade tensions and mixed signals from Washington and Wall Street. While U.S.-China talks quietly resumed, tariffs persisted and business sentiment stayed cautious, contributing to investor uncertainty. May's investments added $111 in annual dividends, keeping me on track with my goal of $100+ monthly income growth and a 7.4% yield on cost.
Positive
Seeking Alpha
one day ago
Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered dividends. Both carry moat-worthy attributes and provide economically essential products and services that make them recession resilient.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 55,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today